Insulin, discovered in 1921, marked the first therapeutic peptide. Since then, synthetic and recombinant technologies have revolutionized their medical application. Today, under HHS Secretary RFK Jr, the administration is actively reclassifying and easing FDA restrictions on various previously banned peptides, sparking intense debate regarding regulatory standards, patient safety, and accessibility